host meet manag observ play key
role drive physician add core driver increas orders/
practic street expect reflect sustain trend see littl
reason regress step pipelin effort continu view
top pick
sinc ad newli order cologuard provid per
quarter new practic addit new record manag believ
jump addit driven increas advertis
increas nation network advertis initi quarter got
bang-for-the-buck given get better advertis rate rep detail
rep start make call practic exist relationship arguabl better
posit add new account core rep given alreadi offic
mani provid alreadi order cologuard increas mani
peopl co-pay respons
biggest driver increas orders/provid like improv payer
coverag improv detail core sale peopl new direct sale hire
complet august better approach detail practic link cowen august
note background definit help still earli worth note
effect activ field week take time order
complet accordingli yield could even evid come
get go new rep start hit stride nation
advertis better rate reach grow materi payer coverag
expand earli reason build
model yet said clear path mathemat revenu
upsid vs current consensu assum add practices/quart
practic complet one cologuard order year would still
penetr doesnt factor expans popul
manag met fda last week regard next step pursuant approv
cologuard use year old popul one way
patient studi enrol support approv uspstf inclus commerci coverag
screen liver lung pancreat mani cancer barrett
esophagu program compani continu build cologuard momentum also
look even bigger broader note adjust forecast
least partial reflect need spend advanc program
continu page
pleas see page report import disclosur
peopl consid averag risk colorect cancer us market
colorect cancer test estim annual believ well
posit captur signific part opportun colorect
cancer screen opportun vastli under-penetrated initi underway
drive increas screen cologuard low competit threat market
signific barrier entri cologuard includ multipl guidelin
cologuard support larg sale market presenc leverag
technolog develop addit product util commerci infrastructur
add new product sale bag given larg market cologuard strong posit
believ grow revenu compound-annual-growth-rate accordingli
outperform rate price target
pace physician add continu
past month
y/i
remain flat due widespread
physicians/week due increas
market spend rep
data pipelin product releas
quicker anticip
provid addit decreas tv/digit
advertis lesser impact
year past rep less
product anticip
new competit blood stool-bas
exact scienc corpor molecular diagnost compani
initi focu earli detect prevent colorect cancer compani
locat madison wisconsin develop non-invas screen test call
cologuard earli detect colorect cancer pre-canc cologuard test
stool-bas screen test design detect specif dna mutat methyl
addit test detect blood stool fda approv cologuard use
non-invas colorect cancer screen test test includ multipl
nation guidelin also develop diagnost test earli detect
liver lung pancreat esophag cancer
manag pre-announc revenu beat januari link note
test deliv vs estimate/guid vs
guidance/expect exceed guidanc expect importantli
compani ad nearli new provid quarter impli
provid ad week knowledg repres provid
ad quarter roughli histor run rate provid
cours quarterli complet orders/provid
compani ad new orders/practic quarter
rel notabl jump
manag indic biggest driver increas orders/provid
like improv payer coverag improv detail core sale
peopl new direct sale hire complet august better approach
detail link cowen august note background manag indic
partnership go well howev ramp effici estim
realli fulli product week quarter fact
order take time complet revenu recogn impact seemingli
like translat complet order revenu
cowen model model current assum provid
complet order modestli better annual
run rate think bia upsid given combin effect
doubl number detail capabl vs
sensit order field detail provid interact
sale repres order mani test provid
interact broader coverag live
sinc ad new provid order cologuard
per quarter norm sinc tv advertis commenc
new practic addit new record
manag believ driven increas advertis
increas nation network advertis initi quarter got
bang-for-the-buck given get better advertis rate rep
detail rep start make call practic exist relationship
like better posit add new account core rep given alreadi
door mani provid yet order cologuard increas
percentag patient cologuard co-pay
cowen model model current assum return new practic
addit per quarter beyond earli relationship may
appropri model conserv possibl outsiz
boost cologuard shini new toy said believ clear bia
upsid follow reason rep get effici time
advertis spend increas pretti materi
improv averag sell price asp larg function enter
payer contract past sever quarter correspond
improv accrual rate predict revenu collect like
less quarterli variabl move forward
cowen model current assum asp view
appropri neither aggress conserv
note continu forecast remain stabl
order/practic rate q/q growth improv new practic
addit return get us revenu forecast
slightli consensu note believ assumpt
like pronounc upsid bia seen seem
clear path revenu
cowen compani
think bia pretti clear keep mind follow
histor new provid addit ad market
campaign tv advertis rather via sale rep agreement
cologuard market increas increas increment
total spend evenli split
addit advertis spend funnel rate
materi lower exact experienc drive market
campaign boost total nation market spend increas spend
effici would like drive increas provid addit
remind began train sale forc octob therefor rep
effect week could begin market cologuard
smaller-than-expect overlap provid rep rep
rep primarili target provid never order cologuard ostens
newli ad rep would caus inflect number cologuard
order provid think could pronounc longer period
time get profici sell cologuard
addit keep mind rep highli motiv sell cologuard
product consid rep target incent base rep
product cologuard moreov possibl cologuard sale
bag give rep time doctor also motiv
partnership afford abil call frequent high
volum prescrib abil call doc doubl detail
capac recent exercis option expand cologuard detail
ob/gyn well manag indic patient visit ob/gyn
elig cologuard older proport grow move
believ sever driver could increas complet order per
provid includ improv complianc rate larger sale forc
new hire complet august like
face volum headwind part due messag patient would
receiv bill cologuard fulli cover insur messag stop
hangov associ continu dissip time
importantli manag note patient co-pay requir
increas sinc last updat compani indic increas payer
coverag pair improv patient messag turn revers headwind
tailwind could drive increas complianc
ad sale rep manag expect rep
becom fulli product sinc field rep larg call doctor
alreadi order expect help drive complet order per practic higher
reiter compani contract payer
medicar rate provid asp model visibl price
transpar payer also elimin risk futur medicar
reimburs rate reduct via pama long-term price stabil appear
much intact
around provid countri work affili health system
howev top health system adopt cologuard manag
believ sale team bit under-sc messag
ineffect
process build health system team
re-engin approach base feedback compani believ also
tool improv messag gain access coverag reduc co-pay
guidelin qualiti measur
compani expect yield return first prong
agreement rep detail pcp advertis get
focu invest commun clearli enthus
prong lot expertis access
ac broaden guidelin recommend screen begin age
rather link note compani start prospect studi
year old popul remain unclear point fda requir larger
studi akin deep-c smaller size cohort possibl garner regulatori
approv indic met fda discuss option expect
updat earn call clear compani would discuss
outcom meet
compani explain decis develop new version cologuard
found accur marker hope increas specif
therefor reduc fals posit rate also increas
throughput lower test cost allow compani achiev gross margin
compani note unclear requir run anoth prospect
studi would take year could use current bank sampl would
take year regardless manag indic commit
continu believ accur liquid biopsi test colorect
cancer detect studi on-going said manag want data improv
anyth publish publicli
manag indic liver liquid biopsi test like next
commerci test compani abl lower cogs/test
price cologuard plan present data year ddw
compani indic sever pipelin program on-going well
includ pancreat cancer liquid biopsi assay compani aim develop
blood-bas assay reduc number unnecessari cyst biopsi
compani also continu invest modest amount lung cancer liquid biopsi
product although program clearli move bit slowli liver liquid
biopsi assay also work assay determin patient
barrett esophagu therefor obviat need mani invas tissu biopsi
blood-bas recurr monitor assay colon liver note
potenti area compani may pursu
would note includ revenu aforement pipelin
product model
increas project oper spend forecast
believ current street
consensu would also translat increas y/i oper
spend could high thought least take initi shot
new estim base detail provid logic follow
 expect increment advertis spend basic run
rate essenti posit fulfil oblig invest
advertising/market part pfe-exa match spend commit
compani recent stand-alone annual run rate per spend said
expect spend given program work roi appear
sale market new hire personnel cost like increas annual
spend add variabl compens could
increment complet hire new direct pcp rep august
expect hire addit compani plan hire gi
specialist expens
promotional/supplement fee expect add expens
 expect expens increas y/i
y/i base program identifi review
compani report cowen compani
cagrcommentstot pre-announc revenu growth preliminari revenu guidanc servic growth cologuard order growth growth complianc rate guid cologuard volum pre-announc volum growth growth rate calcul roll month basisord growth growth order cowen
compani report thomson eikon cowen compani
pre-announc revenu complet expect feb long term long term gross margin goal reiter growth note gm pressur due new facil util amort research develop note pay advertis least match oper opex expect increas q/q evenli split increas expect market spend account roll increment ageement clearli mani unknown benefit time growth best option end agreement approach income/expens interest oper comp oper count mm gross oper scienc consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
reimburs materi expect new competit market campaign
fail drive meaning volum
